Acalabrutinib in Patients with R/R Marginal Zone Lymphoma (MZL)
Physician's Weekly,
In a side-by-side comparison study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia, the Bruton tyrosine…
A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Overview of attention for article published in British Journal of Haematology, July 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (92nd percentile)
-
High Attention Score compared to outputs of the same age and source (94th percentile)
Readers on
- mendeley
- 43 Mendeley